Lumiracoxib Methotrexate

Clinically important, potentially hazardous interactions with acenocoumarol, anagrelide, anticoagulants, bismuth, boswellia, calcium hydroxylapatite, capsicum, cholestyramine, desvenlafaxine, devil s claw, dexamethasone, dexibuprofen, dicumarol, etodolac, evening primrose, flunisolide, ginkgo biloba, ginseng, heparin, ibuprofen, indomethacin, ketoprofen, ketorolac, lumiracoxib, methotrexate, methylprednisolone, nilutamide, NSAIDs, phellodendron, prednisone, resveratrol, reteplase, rivaroxaban, sermorelin, sulfites, tirofiban, triamcinolone, urokinase, valdecoxib, valproic acid, verapamil, warfarin... 

In a double-blind, placebo-controlled study in patients with rheumatoid arthritis given low-dose methotrexate 7.5 to 15 mg weekly, lumiracoxib 400 mg daily for 7 days had no significant effects on the pharmacokinetics of methotrexate. ... 

Hartmann SN,Rordorf CM, Milosavljev S, Branson JM, ChalesGH, JuvinRR, Lafforgue P, Le Parc JM, Tavernier CG, Meyer OC. Lumiracoxib does not affect methotrexate harma-cokinetics in rheumatoid arthritis patients. Ann Pharmacother (2004) 38,1582-7. 

---

See also in sourсe #XX -- [ ]

---